Issues in the Selection of an Antiarrhythmic Agent

Prystowsky, Eric N.
July 1988
Angiology;Jul1988 Part 2, Vol. 39 Issue 7, p639
Academic Journal
Although procainamide has been available, and used, in the treatment of atrial and ventricular arrhythmias for approximately thirty years, its short half-life has made it less than optimal for long-term arrhythmia management in ambulatory patients. Currently available sustained-release preparations provide the same therapeutic benefit with a more tolerable dosage schedule. The pharmacology of procainamide and its basic electro- physiologic properties, dosage schedules, and toxicity are discussed. Finally, the current indications for its use are reviewed.


Related Articles

  • Limitations to antiarrhythmic drug use in patients with atrial fibrillation. Humphries, Karin H.; Kerr, Charles R.; Steinbuch, Michael; Dorian, Paul // CMAJ: Canadian Medical Association Journal;9/28/2004, Vol. 171 Issue 7, p741 

    Background: Of the antiarrhythmic agents currently marketed in Canada, 5 are commonly used to treat atrial fibrillation (AF). The impact of contraindications, warnings and precautions for the use of these drugs in patients with AF is not known. We evaluated the proportion of patients with AF for...

  • Amiodarone-induced pulmonary toxicity. Predisposing factors, clinical symptoms and treatment. Jessurun, G.A.J.; Boersma, W.G.; Crijns, H.J.G.M.; Jessurun, G A; Crijns, H J // Drug Safety;May1998, Vol. 18 Issue 5, p339 

    Amiodarone is frequently used for the treatment of cardiac arrhythmias. Although the therapeutic efficacy of amiodarone has been established, its use is limited by its safety profile. Amiodarone-induced pulmonary toxicity is one of the most life-threatening complications of this therapy. It is a...

  • Clinical Use of Sustained-Release Procainamide in Treatment of Cardiac Arrhythmias. Michelson, Eric L.; McGeehin III, Frank C.; Levin, Barry K. // Angiology;Jul1988 Part 2, Vol. 39 Issue 7, p647 

    Although procainamide has been available, and used, in the treatment of atrial and ventricular arrhythmias for approximately thirty years, its short half-life has made it less than optimal for long-term arrhythmia management in ambulatory patients. Currently available sustained-release...

  • Symptomatic Bradycardia, Syncope, and Prolonged QTc Interval Associated With Dronedarone Therapy. Eppert, Heather Draper; Goddard, Kara B. // Hospital Pharmacy;Apr2012, Vol. 47 Issue 4, p285 

    Objective: To report a case of symptomatic bradycardia, prolonged QT interval, and syncope associated with dronedarone in a patient with atrial fibrillation who was maintained in sinus rhythm.Case Summary: A 58-year-old man presented to the emergency department with a chief complaint of chest...

  • Antimicrobial-Associated QT Interval Prolongation: Pointes of Interest. Owens, Jr., Robert C.; Nolin, Thomas D. // Clinical Infectious Diseases;12/15/2006, Vol. 43 Issue 12, p1603 

    Until recently, cardiac toxicity manifesting in the form of arrhythmias related to QT interval prolongation was uncommonly appreciated within the antimicrobial class of drugs, but it was well described among antiarrhythmic agents. Antimicrobials that are associated with QT prolongation include...

  • P444 Therapeutic and prophylactic effects of oleuropein on ischemic and reperfusion injury of the heart in an in vivo and in vitro rat model. Esmailidehaj, M; Alihosaini, J; Bajoovand, S; Rezvani, ME // Cardiovascular Research;Jul2014, Vol. 103 Issue suppl_1, pS81 

    Purpose: Oleuropein is a very powerful phenolic antioxidant that exists in high concentrations in olive leaves. Several pharmacological benefits have been reported about oleuropein that nearly all of them linked to its antioxidant property. Given that oxidants play an important role in the...

  • Antiarrhythmic properties of a rapid delayed-rectifier current activator in rabbit models of acquired long QT syndrome. Diness, Thomas G.; Yung-Hsin Yeh; Xiao Yan Qi; Chartier, Denis; Tsuji, Yukiomi; Hansen, Rie S.; Olesen, Soren-Peter; Grunnet, Morten; Nattel, Stanley // Cardiovascular Research;Jul2008, Vol. 79 Issue 1, p61 

    Aims: Impaired repolarization in cardiac myocytes can lead to long QT syndrome (LQTS), with delayed repolarization and increased susceptibility to Torsades de Pointes (TdP) arrhythmias. Current pharmacological treatment of LQTS is often inadequate. This study sought to evaluate the...

  • Atrial Remodeling and Novel Pharmacological Strategies for Antiarrhythmic Therapy in Atrial Fibrillation. Jost, N.; Kohajda, Z.; Krist�f, A.; Kov�cs, P. P.; Husti, Z.; Juh�sz, V.; Kiss, L.; Varr�, A.; Vir�g, L.; Baczk�, I. // Current Medicinal Chemistry;Aug2011, Vol. 18 Issue 24, p3675 

    Atrial fibrillation (AF) is the most common arrhythmia in clinical practice. It can occur at any age, however, it becomes extremely common in the elderly, with a prevalence approaching more than 20% in patients older than 85 years. AF is associated with a wide range of cardiac and extra-cardiac...

  • Osiris' IV adult stem cells produce good cardiac data. Lorenzo, Aaron // Medical Device Daily;3/29/2007, Vol. 11 Issue 60, p1 

    The article discusses the effectiveness of Provacel, an adult stem cell therapeutic technology from Osiris Therapeutics. Based on a clinical test, the anti-arrhythmic effects of Provacel lowered the frequency of premature ventricular contractions in the majority of cardiac patients. The health...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics